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cense.Abstract Introduction: Pulmonary compromise in systemic sclerosis (SSc) includes pulmonary
hypertension (PHT) and interstitial lung disease (ILD) which reﬂect speciﬁc pathological insults,
namely, obliterative vasculopathy and ﬁbrosis, respectively. Vascular (endothelial cell) injury and
activation are the earliest and possibly primary events in the pathogenesis of SSc. Being one of
the endothelium-related indices, serum soluble vascular cell adhesion molecule-1 (sVCAM-1) could
be a useful parameter in vascular assessment.
Aim of the work: The aim of this study was to (1) assess the serum level of sVCAM-1 in SSc patients
and (2) investigate any correlation of sVCAM-1with pulmonary involvement (PHTand ILD) anddis-
ease activity.
Patients and methods: This study was carried out on 15 SSc patients and 10 control subjects of
matched age and sex. Each patient was subjected to history taking, full clinical examination,mail.com (A.I. Alzawawy),
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22 A.I. Alzawawy et al.assessment of skin involvement by the modiﬁed Rodnan skin score (mRSS), routine laboratory
investigations, assay of VCAM-1 by the use of ELISA test and multislice CT for assessment
of PHT and ILD.
Results: There was a statistically signiﬁcant increase of serum sVCAM-1 in SSc patients com-
pared to controls (p= 0.0069). There were no statistically signiﬁcant differences between
sVCAM-1 levels in patients with and without PHT, patients with mild ILD and those with mod-
erate to severe ILD as well as patients with limited and diffuse SSc. No signiﬁcant correlation
could be found in SSc patients between sVCAM-1 levels and mRSS (r= 0.186, p= 0.661), serum
creatinine (r= 0.379, p= 0.191) and different grades of ILD (r= 0.154, p= 0.609). There
was a statistically signiﬁcant correlation between serum sVCAM-1 level and CRP (r= 0.852,
p= 0.001).
Conclusion: The increased level of sVCAM-1 among the studied SSc patients could not be strictly
attributed to pulmonary endothelial cell activation/damage and its pathologic role could not be
veriﬁed in this respect by this study. The pattern of its correlation with selected disease activity
indices pointed out to its link to the inﬂammatory stage of SS. Consequently, it could be consid-
ered as a non speciﬁc marker of inﬂammation irrespective to the type and extent of systemic
organ involvement.
 2010 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Systemic sclerosis (SSc), scleroderma, is a disorder character-
ized by widespread vascular injury and ﬁbrosis of the skin
and visceral organs [1]. Pulmonary involvement, which fre-
quently complicates SSc, provokes low quality of life and poor
expectation of survival [2]. Pulmonary compromise in SSc in-
cludes pulmonary hypertension (PHT) and interstitial lung dis-
ease (ILD) which reﬂect speciﬁc pathological insults, namely,
obliterative vasculopathy and ﬁbrosis, respectively [3,4].
Generally, patients with diffuse SSc are at risk of having pro-
gressive ILD, while those with limited SSc may develop ILD but
are also at risk of having PHT in the absence of interstitial changes,
a complication most typical of a long-standing disease [4].
The pathogenesis of SSc involves interplay between obliter-
ative vasculopathy in multiple vascular beds, inﬂammation
and autoimmunity, and progressive ﬁbrosis [5]. Vascular
(endothelial cell) injury and activation are the earliest and pos-
sibly primary events in the pathogenesis of SSc [6]. The causes
that might trigger endothelial cell injury are granzymes, endo-
thelial cell-speciﬁc autoantibodies, vasculotropic viruses,
inﬂammatory cytokines, or reactive oxygen radicals generated
during ischemia/reperfusion [7].
The pathogenesis of SSc also involves an interaction be-
tween endothelial cells and T cells. Endothelial cells activation
(injury) leads to adherence and migration of the peripheral
blood T cells through the vessel wall into the extracellular
space. This leads to activation of ﬁbroblasts and myoblasts
and accumulation of extracellular matrix and subsequent
ﬁbrosis of the skin and internal organs and hypertrophy/
hyperplasia of the arterial wall of pulmonary and renal vessels
[8]. The T cells (via a set of receptors) adhere to endothelial
cells by a set of counter-receptors adhesion molecules includ-
ing vascular cell adhesion molecule-1 (VCAM-1). The coun-
ter-receptorsVCAM-1 are overexpressed on the activated
endothelial cell surface. They undergo shedding and their sol-
uble forms, sVCAM-1 are detectable in the serum and consid-
ered to be markers of endothelial cell activity or injury [9,10].
Thus, endothelial cell injury and activation participate in
the pathogenesis of both PHT (via obliterative vasculopathy)[4] and ILD (via direct and indirect roles in inducing ﬁbroblast
activation that leads ultimately to ﬁbrosis) [11].
Being one of the endothelium-related indices, sVCAM-1
could be a useful parameter in vascular assessment [12]. It
was found to be increased in patients with SSc compared to
healthy control subjects [10,13–15] and its elevation was dom-
inated in patients with internal organ involvement [10] and
correlated with pulmonary ﬁbrosis [16]. Moreover, sVCAM-
1 is a recognized marker of SSc disease activity and a possible
marker of disease severity [12,17,18].
However, in one study sVCAM-1 (among other endothelial
cell activity markers) was found to be increased in SSc patients
compared to normal values but the difference was not signiﬁ-
cant and not related to disease activity [19]. Furthermore, in
another study, evidence of endothelial cell activity in SSc asso-
ciated with PHT was inconsistent, with normal sE-selectin and
normal sVCAM-1 in the sera of patients with limited SSc and
PHT [20].
Thus, based on these controversial results, the signiﬁcance
of sVCAM-1 as a marker of vascular injury related to pulmon-
ary involvement in SSc patients as well as its reﬂection of dis-
ease activity needs further evaluation in a trial to deﬁne its
pathogenetic role in this respect.
Therefore the aim of this study was to (1) assess the serum
level of sVCAM-1 in SSc patients and (2) investigate any cor-
relation of sVCAM-1 with pulmonary involvement (PHT and
ILD) and disease activity.
Study design: This study is a cross-sectional case-control
one.2. Patients and methods
2.1. Subjects
The study was carried out on 15 patients fulﬁlling the criteria
for the classiﬁcation and diagnosis of progressive systemic scle-
rosis [21] and 10 control subjects of matched age and sex. They
were recruited from Rheumatology Outpatient Clinic, Faculty
of Medicine, Alexandria University. Cigarette smokers were
Table 1 sVCAM-1 level (pg/ml) among scleroderma patients
and controls.
Group I Group II p
Mean 1931.15 1214.33 0.0069
SD 593.52 324.29
Group I = scleroderma patients.
Group II = controls.
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each participant and the study was approved by the local eth-
ical committee.
Each patient was subjected to thorough history taking and
clinical examination including evaluation of skin involvement
using the modiﬁed Rodnan skin score (mRSS) of 17 sites.
Patients were then subgrouped into diffuse and limited types
[22]. Systemic affection especially pulmonary and renal
involvement was also evaluated.
Assessment of disease activity in this study was based on
CRP level and mRSS [23,24].
2.2. Laboratory investigations
CRP and serum urea and creatinine (to exclude renal affec-
tion) [25] were assessed for each subject. The sVCAM-1 was
assayed in serum samples by standard sandwich ELISA kits
from medsystemsgmbh Vienna Austria. A standard curve
was established for each assay plate. Normal ranges were
based on analysis of healthy sera by the manufacturers [26].
2.3. Radiological examination
Multislice CT equipped by multi slice detector technology was
performed for assessment of pulmonary hypertension and
parenchymal lung affection [27–29].
The scans were assessed by an experienced radiologist. The
reader knew that patients had SSc but was blinded to other
clinical information. The scan protocol required all sites to ob-
tain scans using a beam potential of 140 kV and a beam cur-
rent of 100 mA with 1-mm or 2-mm collimation at 10-mm
intervals from the lung apices to the bases and to reconstruct
images with a high-spatial-frequency algorithm. Patients
underwent scanning during suspended end-inspiration in the
prone position without IV contrast material.
For comprehensive reviews, each lung was divided into
three zones: upper (lung apex to aortic arch); middle (aortic
arch to inferior pulmonary veins); and lower (inferior pulmon-
ary veins to lung bases). The following CT scan ﬁndings were
recorded:
 Multislice CT ﬁndings of pulmonary ﬁbrosis including:
architectural distortion, subpleural cysts or honeycombing,
irregular reticular opacities, interlobular septal thickening,
traction bronchiectasis and bronchiolectasis, visceral pleu-
ral thickening and parenchymal micronodules.
 Ground-glass opacity which may indicate acute inﬂamma-
tion (alveolitis).
 Honeycombing which favors a histologic usual interstitial
pneumonitis (UIP) pattern.
 Mixed reticulation and ground-glass opacity with little or
absent honeycombing which favor histologic nonspeciﬁc
interstitial pneumonia (NSIP).
 Distribution of disease: (1) subpleural and basal predomi-
nant ﬁbrosis, (2) a less marked involvement of the upper
lobes favors SSc or other collagen vascular disease as the
etiologic cause of the UIP pattern rather than ILD or
chronic hypersensitivity pneumonitis.
 According to scoring system of ILD, it is divided into:
0 = absent abnormality, 1 = mild(one zone abnormali-
ties), 2 = moderate (two zones abnormalities) and
3 = severe (three zones abnormalities). Multislice CT is areliable and reproducible diagnostic imaging method for
the assessment of the pulmonary artery diameter in order
to predict the pulmonary artery pressure (PAP) with evalu-
ation of the relationship of the diameter with age, gender
and body surface area. An electronic cursor was used to
measure the widest diameter perpendicular to the long axis
of the main pulmonary artery bifurcation level. The outer
limits of the contrast were used to determine the vessel
diameter.
2.4. Statistics
The collected data were coded, tabulated and statistically ana-
lyzed using a Microsoft statistical package of social science
version 15 (SPSS-15). Variables were presented as frequencies
or mean ± SD. Nonparametric statistical methods were used
for data analysis: Mann-whitney U test for comparison be-
tween groups and Spearman’s rank correlation test for deter-
mination of the relationships between quantitative variables.
p values less than 0.05 were considered signiﬁcant.
3. Results
The study was carried out on 15 patients. Thirteen were fe-
males (86.7%) and 2 were males (13.3%). Their ages ranged
from 18 to 43 years with a mean of 32.1 years, in addition to
10 age and sex-matched controls (3 were males and 7 were fe-
males). The mean disease duration of the studied patients was
10.4 years.
On clinical examination all SSc patients suffered from Ray-
naud’s phenomenon and their modiﬁed Rodnan skin score
ranged from 15 to 48 with a mean of 28.17 ± 16.17. Eight
(53.3%) patients were of diffuse type and 7 (46.7%) patients
were of limited type.
Table 1 shows a statistically signiﬁcant increase of the mean
serum sVCAM-1 level in SSc patients (mean ± SD=
1931.15 ± 593.52 pg/ml with a range of 945–3070 pg/m) com-
pared to controls (whose mean ± SD= 1214.33 ± 324.29
and range = 812–1642), (U= 0.911 and p= 0.0069).
Table 2 shows other laboratory characteristics of SSc pa-
tients. All patients showed normal serum urea and creatinine
as well as increased CRP as compared to the upper limits of
normality of the laboratory reference values (41, 1.1 and
6 mg/dl), respectively.
Radiological study (Table 3) reveals that only 4 (26.7%) pa-
tients were diagnosed as PHT while 11 (73.3%) patients did
not have evidences of PHT. Moreover, 8 (53.3%) patients
had grade I ILD (mild affection), while 7 (46.7%) had moder-
ate to severe ILD, i.e., 4 (26.7%) patients had grade II ILD
(moderate affection) and 3 (20%) patients had grade III ILD
(severe affection).
Table 5 Correlation between serum sVCAM-1 levels among
SSc patients and different studied measurements.
Parameter R p
Modiﬁed Rodnan skin score 0.186 0.661
Serum creatinine 0.379 0.191
1LD grades 0.154 0.609
CRP 0.852 0.001*
ILD= interstitial lung disease.
* p is signiﬁcant if <0.05.
Table 2 Laboratory characteristics of SSc patients.
Parameter SSc patients
Mean ± SD Range
Serum urea (mg/dL) 27.95 ± 7.06 17–39
Serum creatinine (mg/dL) 0.89 ± 0.2 0.5–1.1
CRP (mg/dL) 18.69 ± 8.55 8–32
Table 3 Radiological assessment of SSc patients.
Pulmonary hypertension ILD
(+) () Mild Mod-severe
4/15 11/15 8/15 7/15
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– Mediastinal adenopathy was found, with increased preva-
lence in more extensive lung disease.
– Esophageal dilation was present on CT in 13 (86.7%) of
SSc patients with diffuse lung disease. Six patients had
grade I and 7 had grade II esophageal dilatation while 2
patients did not have features of esophageal dilatation.
Table 4 demonstrates the comparison of the mean serum
sVCAM-1 level among different categories of SSc patients.
There was no statistically signiﬁcant difference between
patients with limited and diffuse skin affection (U= 0.22,
p= 0.662), patients with PHT and those without PHT
(U= 0.711, p= 0.475) and patients with different grades of
ILD (U= 0.223, p= 0.715) regarding the mean serum
sVCAM-1 level.
Table 5 demonstrates the correlation between the serum
sVCAM-1 levels among SSc patients and different studied
parameters. No signiﬁcant correlations could be found be-
tween the serum sVCAM-1 levels and the modiﬁed Rodnan
skin score (r= 0.186, p= 0.661), serum creatinine
(r= 0.379, p= 0.191) and different grades of ILD
(r= 0.154, p= 0.609). Only a signiﬁcant positive correla-
tion was found between serum sVCAM-1 level and CRP levels
(r= 0.852, p= 0.001).Table 4 Comparison of the mean serum sVCAM-1 level
among different categories of SSc patients.
SSc category Serum sVCAM-1
mean ± SD
U p
Skin aﬀection
Diﬀuse 2002.5 ± 725.1 0.22 0.662
Limited 1870 ± 566.89
Pulmonary hypertension (PHT)
(+) 1763 ± 572.74 0.711 0.475
() 2067 ± 571.62
Interstitial lung disease
Mild (ILD) 2037.77 ± 615.11 0.223 0.715
Moderate to severe (ILD) 1868.33 ± 475.4
p is signiﬁcant if <0.05.4. Discussion
Pulmonary involvement has emerged as the leading cause of
mortality and the principal cause of morbidity in SSc [4]. Pul-
monary vascular changes in SSc are suspected to occur at an
early stage. The changes include gaps between endothelial cells
(EC), apoptosis, endothelial activation with inﬂammatory cells
recruitment, procoagulant state and intimal proliferation and
adventitial ﬁbrosis which may lead to vascular obliteration
[11,30–33]. Expression of adhesion molecules including s-
VCAM-1 is critical in SSc due to the early interaction between
EC and mononuclear cells [34].
The present study revealed signiﬁcant increase in the mean
serum sVCAM-1 level in SSc patients compared to control
subjects. This generally could be related to the ongoing EC
damage in different organs in SS patients with subsequent
upregulation and shedding of various markers of EC activa-
tion including sVCAM-1 [10,14]. Other studies have also dem-
onstrated the same result in SSc patients (whether diffuse or
limited) compared to healthy controls [35–39]. However, in
one study, although the serum level of sVCAM-1 was higher
in SSc patients, yet it did not reach a signiﬁcant level compared
to controls; then the mean values after one year did not differ
from the entry values [19].
Further subgrouping of the studied patients revealed no sig-
niﬁcant difference of the mean serum sVCAM-1 level in pa-
tients with PHT and those without PHT as well as patients
with mild ILD and those with moderate-severe ILD, although
it was still higher in each subgroup compared to healthy con-
trols. That is, sVCAM-1 level was signiﬁcantly higher in SSc
patients irrespective of the type and extent of pulmonary
involvement. This may denote that the source of sVCAM-1
in the studied patients was not the activated pulmonary EC
i.e. the mechanism leading to pulmonary vascular lesion may
not involve sVCAM-1. This is further supported by the lack
of correlation between the level of sVCAM-1 in the studied pa-
tients and the degree of ILD. Nevertheless, the lung pathology
(whether PHT or ILD) in the studied sample could be still
attributed to and initiated by the activated pulmonary EC in
response to various stimuli with upregulation of activation
markers (other than sVCAM-1) which were not assessed in this
study, such as soluble intercellular adhesion molecule-1 (sI-
CAM-1) and sE-selectin [10,20] or the lack of signiﬁcant re-
sults could be related to the small number of the studied
sample.
In contrast to the present results, several studies have found
increased level of sVCAM-1 in SSc patients with ILD com-
pared to those without [10,17]. They concluded that these acti-
vation markers may reﬂect the extent of internal organ
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ical role [10].
The results of the present study also revealed no signiﬁcant
difference of the mean serum sVCAM-1 level in patients with
diffuse versus those with limited SSc (although the levels in
both groups are still higher than the controls). In addition,
there was no signiﬁcant correlation between the sVCAM-1 le-
vel and the extent of skin involvement (mRSS). This also sig-
niﬁes that the source of s-VCAM-1 was not the vascular EC
of the skin. This is in agreement with a study carried out by
Alekperov et al., in which there was a signiﬁcant increase in
the mean values of sVCAM-1 in SSc patients compared to con-
trols, but no difference was found between those with diffuse
and limited forms [38]. On the other hand, 2 studies performed
by Ihn et al. and Valentini et al. have found signiﬁcant increase
of sVCAM-1 in patients with diffuse compared to those with
limited forms of SSc and stated that this marker may reﬂect
the extent of skin involvement [16,40]. More speciﬁcally, some
studies have found signiﬁcant increase of the in situ expression
of sVCAM-1 in SSc versus normal endothelium and stratum
granulosum in skin biopsies [36,41]. In one study the elevated
serum sVCAM-1 correlated positively well with their in situ
activity (EC and ﬁbroblasts in lesional skin) [41].
It is to be noticed that the studied patients did not exhibit fea-
tures of renal involvement (whether at the clinical or laboratory
levels). This may signify that the renal vascular endothelium can
not account for the increased level of sVCAM-1 in the current
study, unlike what has been proven by Stratton et al. They
found high levels of adhesion molecules including sVCAM-1
in SSc patients with renal crisis and concluded that in such con-
ditions the EC appear to be in a highly activated state [20].
Thus it may be assumed that the increased level of sVCAM-
1 in the studied SSc patients together with the lack of signiﬁcant
correlations with pulmonary, skin and renal indices and the sig-
niﬁcant correlation with CRPmay be attributed to the non spe-
ciﬁc inﬂammation in scleroderma rather than speciﬁc organ
affection. Moreover, some authors reported that in addition
to EC, sVCAM-1 expression was found in stromal ﬁbroblasts
in bone marrow, lymphoid dendritic cells and tissue macro-
phages [42]. Thus it is possible that only a minor fraction of
sVCAM-1 is produced by vascular EC. The latter explanation
accounted for the inconsistent results obtained by Stratton
et al regarding pulmonary involvement in SSc patients [20].
Unlike other connective tissue diseases, deﬁning disease
activity in SSc is more difﬁcult as there is no clear cut distinction
between ﬂares and quiescent phases particularly in limited SSc
[42]. However, 2 stages can be still identiﬁed although with dif-
ﬁculty in longstanding indolent limited SSc. The ﬁrst is the
inﬂammatory stage (potentially reversible and reﬂects activity)
in which there is EC damage or activation with stimulation of
ﬁbroblasts. The second is the irreversible stage (reﬂects damage)
inwhich there are vascular occlusion and interstitial ﬁbrosis [43].
Among the activity indices used in this study is the mRSS
which reﬂects the extent of skin involvement. Its mean value
was >14 which is accepted by the European Scleroderma
Study Group (EScSG) to reﬂect an active disease [23]. How-
ever, the lack of relationship between sVCAM-1 and the extent
of skin involvement (whether its non signiﬁcant difference be-
tween patients with diffuse and limited SSc or its lack of cor-
relation with (mRSS)) makes the link between sVCAM-1
and the skin pathology a remote possibility in this study (as
previously mentioned).Another disease activity index namely the CRP was found
to be increased among the studied patients together with a
signiﬁcant positive correlation with sVCAM-1. Actually,
CRP was considered among the disease activity indices in
an earlier version of the EScSG disease activity criteria on
the univariate analysis [24]. Our result is in agreement with
Inh et al., who stated that this may reﬂect the level of
inﬂammation among SSc patients (as CRP is a non speciﬁc
marker of inﬂammation) [16]. In SSc the serum level of
adhesion molecules may increase due to chronic exposure
to different cytokines [16]. In this context, one study found
increased expression of VCAM-1 and TNFa and IL-8 in
skin biopsies taken from early (inﬂammatory stage) SSc
[39]. Moreover, several studies (using different disease activ-
ity measures) have generally found increased serum level of
sVCAM-1 in SSc patients with active disease compared to
those with inactive non progressive disease [36,38,41].
In conclusion, the increased level of sVCAM-1 among the
studied SSc patients could not be strictly attributed to pulmon-
ary EC activation/damage. Accordingly, its pathologic role
could not be veriﬁed in this respect. Moreover, the pattern
of its correlation with selected disease activity indices pointed
out to its link to the inﬂammatory stage of SSc. Consequently,
it could be considered as a non speciﬁc marker of inﬂammation
irrespective to the type and extent of systemic organ involve-
ment and hence it may not be a therapeutic target in pulmon-
ary affection in SSc.
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